THE SIGNIFICANCE OF ARTERIAL WALL STIFFNESS ASSESSMENT FOR METABOLIC SYNDROME
https://doi.org/10.15829/1560-4071-2015-12-45-49
Abstract
Aim. To evaluate the usefulness of the pulse wave velocity parameter (PWV) in aorta as an additional prognostic criteria for target organs damage and hence higher cardiovascular risk (CVR) in patients with metabolic syndrome (MS).
Material and methods. Totally 74 normotensive asymptomatic for cardiovascular disorders patients studied, with MS, low and intermediate risk by SCORE (77,0% males, mean age — 45,1±5,0 y.). We performed the assessment of lipid profile, glucose profile, glomerular filtration rate, microalbuminuria (MAU), performed triplex brachiocephal arteries scanning, echocardiography, bifunctional 24-hour monitoring of blood pressure with PWV measurement in aorta. The value of PWV in aorta taken ≥7,9 m/s corresponds with carotid-femoral PWV >10 m/s and in this study it has been used as the criteria of early vascular ageing (EVA) for the selected age diapason of patients.
Results. Higher values of PWV in aorta had patients with MAU (8,5±0,3 m/s vs. 7,6±0,7 m/s, р<0,001), carotid atherosclerosis (8,4±0,3 m/s vs 7,6±0,7 m/s, р<0,001), hypertrophy of carotid arteries wall (CA) (7,9±0,6 m/s vs. 7,5±0,7 m/s, р<0,05), left ventricle diastolic dysfunction (DD LV) (8,3±0,6 m/s vs. 7,6±0,6 m/s, р<0,01). The participants with MS and aortic PWV ≥7,9 m/s had significantly more prevalent carotid atherosclerosis (36,4% vs. 16,2%, р<0,05) and DD LV (33,3% vs. 16,2%, р<0,05). The usage of the value of aortic PWV ≥7,9 m/s made it to select among the patients with MS 100% persons with subclinical carotid atherosclerosis and MAU, 91,7% participants with DD LV, 66,7% persons with carotid arteries wall hypertrophy.
Conclusion. It is aimful, to the patients with MS and low or moderate SCORE risk in case of the PWV at the level for EVA criteria, to perform screening of organ damage, firstly, subclinical atherosclerosis, for consequent reclassification of EVA and reconsideration of the volume of necessary prevention procedures.
About the Authors
M. A. Druzhilov
Medical-Sanitry Institution of FSS by Karelia Republic
Russian Federation
Petrozavodsk
Russian Federation
Petrozavodsk
O. Yu. Druzhilova
Medical-Sanitry Institution of FSS by Karelia Republic
Russian Federation
Petrozavodsk
Russian Federation
Petrozavodsk
V. V. Otmakhov
Medical-Sanitry Institution of FSS by Karelia Republic
Russian Federation
Petrozavodsk
Russian Federation
Petrozavodsk
T. Yu. Kuznetsova
Petrozavodsk State University
Russian Federation
Petrozavodsk
Russian Federation
Petrozavodsk
References
1. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-701.
2. Poirier P, Giles Т, Bray G, et al. Obesity, cardiovascular disease: pathophysiology, evaluation, effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
3. The consensus of experts on a multidisciplinary approach to the management, diagnosis and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention 2013; 12(6): 41-81. Russian (Консенсус экспертов по междисциплинарному подходу к ведению, диагностике и лечению больных с метаболическим синдромом. Кардиоваскулярная терапия и профилактика 2013; 12(6): 41-81).
4. Flegal K, Kit B, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories. JAMA 2013; 309(1): 71-82.
5. Chumakova GA, Veselovskaya NG, Gritsenko OV, et al. Metabolic syndrome: challenging and unresolved issues Russ J Cardiol 2014; 3(107): 63-71. Russian (Чумакова Г.А., Веселовская Н.Г., Гриценко О.В. и др. Метаболический синдром: сложные и нерешенные проблемы. Российский кардиологический журнал 2014; 3(107): 63-71).
6. Iacobellis G, Ribaudo M, Assael F, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003; 88(11): 5163-68.
7. Veselovskaya NG, Chumakova GA, Ott AV, et al. A non-invasive marker of insulin resistance in patients with obesity. Russ J Cardiol 2014; 6(104):28-32. Russian (Н.Г. Веселовская, Г.А. Чумакова, А.В. Отт. Неинвазивный маркер инсулинорезистентности у пациентов с ожирением. Российский кардиологический журнал 2014; 6(104): 28-32).
8. Druzhilov MA, Beteleva YuE, Kuznetsova TYu. Epicardial adipose tissue thickness — an alternative to waist circumference as a stand-alone or secondary main criterion in metabolic syndrome diagnostics? Russ J Cardiol 2014; 3(107): 76-81. Russian (Дружилов М.А., Бетелева Ю.Е., Кузнецова Т.Ю. Толщина эпикардиального жира — альтернатива окружности талии как самостоятельный или второй основной критерий для диагностики метаболического синдрома? Российский кардиологический журнал 2014; 3(107): 76-81).
9. Nilsson P. Hemodynamic Aging as the Consequence of Structural Changes Associated with Early Vascular Aging. Aging and Desease 2014; 5(2): 109-13.
10. Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. Eur Heart J 2010; 31: 2338-50.
11. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2013; 25(63): 636-46.
12. Posokhov IN. Pulse wave velocity 24-hour monitoring with one-site measurements by oscillometry. Medical Devices: Evidence and Research 2013; 6: 11-5.
13. Sugawara J, Hayashi K, Tanaka H, et al. Carotid–femoral pulse wave velocity: Impact of different arterial path length measurements. Artery Research 2010; 4: 27-31.
14. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertension 2013; 31: 1281-357.
15. Druzhilov MA, Otmakhov VV, Beteleva YuE, et al. Subclinical vessel lesion in normotensive patients with abdominal obesity: focus on arterial stiffness. System Hypertension 2013; 10(2): 46-52. Russian (Дружилов М.А., Отмахов В.В., Бетелева Ю.Е. и др. Субклиническое поражение сосудов у нормотензивных пациентов с абдоминальным ожирением: фокус на артериальную жесткость. Системные гипертензии 2013; 10(2): 46-52).
Review
For citations:
Druzhilov M.A., Druzhilova O.Yu., Otmakhov V.V., Kuznetsova T.Yu. THE SIGNIFICANCE OF ARTERIAL WALL STIFFNESS ASSESSMENT FOR METABOLIC SYNDROME. Russian Journal of Cardiology. 2015;(12):45-49. (In Russ.) https://doi.org/10.15829/1560-4071-2015-12-45-49
Views:
630
Email this article 